OVM-200 Phase 1 Clinical Trial featured on TV

The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022.

It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients.

Professor Shisong Jiang, Chief Scientific Officer and Founder of OVM said:

We see the potential benefits of a vaccination approach both in stimulating the body’s immune system to attack the cancer and also, in future trials, enhancing the efficacy of other immune-oncology agents. This Phase I trial is a first step towards having effective cancer vaccines.

Read the full article and watch the video report here:  Chorley mum with ovarian cancer first in North West to get new vaccine trialled at the Christie